News coverage about Insys Therapeutics (NASDAQ:INSY) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Insys Therapeutics earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 44.6003163774844 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Report: Drug company faked cancer patients to sell drug – KOAT Albuquerque (koat.com)
- INSYS Therapeutics, Inc. (INSY)- Stocks Carrying Extraordinary Performance Assessment – NASDAQ Times (nasdaqtimes.com)
- Report: Drug company faked cancer patients to sell drug – CNN (cnn.com)
- Nemus Bioscience CEO Talks ‘Waves Of Dominance’ In The Cannabis Therapeutics Industry (benzinga.com)
- Health Brief: Report Says Insys Used ‘Likely Illegal’ Tactics to Push Opioid (morningconsult.com)
Several brokerages recently weighed in on INSY. Royal Bank Of Canada set a $16.00 price target on Insys Therapeutics and gave the stock a “buy” rating in a research note on Saturday, June 3rd. Zacks Investment Research raised Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 price target on the stock in a research note on Wednesday, July 12th. BidaskClub raised Insys Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 8th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Insys Therapeutics in a research note on Tuesday, July 4th. Finally, Piper Jaffray Companies set a $10.00 price target on Insys Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $13.25.
Shares of Insys Therapeutics (INSY) opened at 9.58 on Tuesday. The company has a 50-day moving average price of $9.88 and a 200 day moving average price of $11.29. The stock’s market capitalization is $696.43 million. Insys Therapeutics has a 52 week low of $8.70 and a 52 week high of $15.23.
Insys Therapeutics (NASDAQ:INSY) last issued its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.12. The business had revenue of $42.60 million during the quarter, compared to analyst estimates of $36.90 million. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. Insys Therapeutics’s revenue was down 38.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.13 EPS. Equities analysts forecast that Insys Therapeutics will post ($0.29) EPS for the current fiscal year.
In related news, CEO Saeed Motahari purchased 5,400 shares of the business’s stock in a transaction dated Wednesday, June 14th. The shares were acquired at an average cost of $11.10 per share, for a total transaction of $59,940.00. Following the acquisition, the chief executive officer now owns 9,900 shares of the company’s stock, valued at approximately $109,890. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder John N. Kapoor Trust Dated Sept purchased 17,500 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was bought at an average price of $8.93 per share, for a total transaction of $156,275.00. Following the completion of the acquisition, the insider now directly owns 31,982 shares in the company, valued at approximately $285,599.26. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 28,400 shares of company stock valued at $265,275. 67.90% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/09/12/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-insys-therapeutics-insy-stock-price.html.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.